Though most patients with AML have VEN-sensitive disease at diagnosis, primary refractory disease can be seen in patients with mutations in TP53 and/or mutations in activating kinase pathways (such as RAS, PTPN11, CBL) (38). This evidence concerns the gene TP53 and acute myeloid leukemia.